夹在放射肿瘤病例费率(ROCR)与困境之间:改进拟议的放射肿瘤替代支付模型
研究比较3大中心历史报销与全国Medicare样本同ROCR拟议基础费率的差异,并检验治疗与疾病特征是否与费率差异相关。结果显示ROCR基础费率使Mayo Clinic和Medicare研究可识别文件分别平均降低2.4%和2.9%,治疗意图和分期与更高历史报销相关。作者认为姑息性 episode 可考虑独立费率及缩短周期,并按分期应用基础费率修正因子。
要点
- ROCR基础费率较历史报销在Mayo Clinic和Medicare样本中分别平均降低2.4%和2.9%。
- Mayo Clinic数据中,治疗意图(根治 vs 姑息)与12/12适用癌种更高历史报销相关(+$477至+$7417;P≤.05)。
- 分期(III-IV vs I-II)与8/12适用癌种更高历史报销相关(+$1169至+$3917;P≤.05)。
核心结论
- 数据提示ROCR基础费率较历史按服务付费(FFS)报销在每个癌种上平均降低≤3%,可能产生ROCR国会批准所需的Medicare节省。
- 与未来FFS报销比较需考虑额外因素如立体定向低分割使用增加、拟议FFS费率削减和通胀更新。
- 作者认为姑息性 episode 可考虑独立费率并缩短周期时长(≤30天)。
- 作者认为按癌症分期应用基础费率修正因子可能减轻根治性晚期患者量大的机构(如农村独立中心)的报销不成比例减少。
研究设计与样本
- 研究使用Mayo Clinic 2017至2020年电子病历数据和Medicare 5%研究可识别文件B部分索赔,按ROCR支付方法计算15种癌症的90天历史 episode 报销率。
- Mayo Clinic数据按疾病和治疗特征分层,并进行多元线性回归评估这些变量与历史 episode 报销率的关联。
- Mayo Clinic纳入3498例患者 episode,研究可识别文件纳入480526例。
主要发现
- 两个数据集中,25%的脑转移和13%的骨转移 episode 包含≥2个疗程,疗程间平均51天。
- 涵盖全部15种癌症,ROCR基础费率较历史报销使Mayo Clinic和研究可识别文件的费率分别平均降低2.4%和2.9%。
- Mayo Clinic数据多变量分析中,治疗意图(根治 vs 姑息)与12/12适用癌种更高历史报销相关(+$477至+$7417;P≤.05)。
- 分期(III-IV vs I-II)与8/12适用癌种更高历史报销相关(+$1169至+$3917;P≤.05)。
临床怎么用
- 作者认为姑息性 episode 可考虑独立费率并缩短周期时长(≤30天)。
- 作者认为按癌症分期应用基础费率修正因子可能减轻根治性晚期患者量大的机构(如农村独立中心)的报销不成比例减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Radiation Oncology Case Rate (ROCR) aims to shift radiation reimbursement from fee-for-service (FFS) to bundled payments, which would decouple fractionation from reimbursement in the United States. This study compares historical reimbursement rates from 3 large centers and a national Medicare sample with proposed base rates from ROCR. It also tests the impact of methodological inclusion of treatment and disease characteristics to determine if any variables are associated with greater rate differences that may lead to inequitable reimbursement. METHODS AND MATERIALS: Using Mayo Clinic electronic medical record data from 2017 to 2020 and part B claims from the Medicare 5% research identifiable files, episodic 90-day historical reimbursement rates for 15 cancer types were calculated per the ROCR payment methodology. Mayo Clinic reimbursement rates were stratified by disease and treatment characteristics and multiple linear regression was performed to assess the association of these variables on historical episode reimbursement rates. RESULTS: From Mayo Clinic, 3498 patient episodes were included and 480,526 from the research identifiable files. From both data sets, 25% of brain metastases and 13% of bone metastases episodes included ≥2 treatment courses with an average of 51 days between courses. Accounting for all 15 cancer types, ROCR base rates resulted in an average -2.4% and -2.9% reduction in rates for Mayo Clinic and the research identifiable files respectively compared with historical reimbursement. On multivariate analysis of Mayo Clinic data, treatment intent (curative vs palliative) was associated with higher historical reimbursement (+$477 to +$7417; P ≤.05) for 12 out of 12 applicable cancer types. Stage (III-IV vs I-II) was associated with higher historical reimbursement (+$1169 to +$3917; P ≤ .05) for 8 out of 12 applicable cancer types. CONCLUSIONS: Our data suggest ROCR base rates introduce an average ≤3% reimbursement rate decrease compared with historical FFS reimbursement per cancer type, which could produce the Medicare savings required for congressional approval of ROCR. Estimating comparisons with future FFS reimbursement would require consideration of additional factors such as the increased utilization of hypofractionation, proposed FFS rate cuts, and inflationary updates. A distinct rate and shortened episode duration (≤30 days) should be considered for palliative episodes. Applying a base rate modifier per cancer stage may mitigate disproportionate reductions in reimbursement for facilities with a higher volume of curative advanced-stage patients such as freestanding centers in rural settings.
引用
- Bush A, Liu CM, Rula EY, et al. Caught Between a Radiation Oncology Case Rate (ROCR) and a Hard Place: Improving Proposed Radiation Oncology Alternative Payment Models. Int J Radiat Oncol Biol Phys. 2024. PMID: 38986915. doi:10.1016/j.ijrobp.2024.06.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。